Optimal cancer care across the spectrum of life and disease

American Journal of Managed Care

Volumn 14, Issue 5, 2008, Pages 262-264

  Lyman, Gary H ^a   Hauser, Robert S ^b  

^a DUKE CANCER INSTITUTE   (United States)

^b Geriatric Oncology Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AFRICAN AMERICAN; ALTERNATIVE MEDICINE; ANEMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; COMORBIDITY; EARLY DIAGNOSIS; EDITORIAL; FATALITY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; LUNG CANCER; NEUTROPENIA; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; UNITED STATES; CANCER CENTER; CANCER THERAPY; NEOPLASM; SPECTRUM;

HEALTH CARE COSTS; HUMANS; MASS SCREENING; MEDICAL ONCOLOGY; NEOPLASMS; UNITED STATES;

EID: 43949145632     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (32)

1. Catlin A, Cowan C, Hartman M, Heffler S; National Health Expenditure Accounts Team. National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood). 2008;27(1):14-29.
2. Brown ML, Yabroff KR. Economic impact of cancer in the United States. In: Schottenfeld D, Fraumeni JF; eds. Cancer Epidemiology. NewYork, NY: Oxford University Press; 2006:202-214.
3. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8)(suppl):IV-104-IV-117.
4. Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Prac Oncol. 2007;4(11):643-656.
5. Yabroff KR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007;99(1):14-23.
6. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
7. Balducci L, Hardy CL, Lyman GH. Hemopoiesis and aging. Cancer Treat Res. 2005;124:109-134.
8. Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncology Hematol. 2004;50(2):129-146.
9. Lyman GH. Essentials of clinical decision analysis: a new way to think about cancer and age. In: Balducci L, Lyman GH, Erschler W, Extermann M, eds. Comprehensive Geriatric Oncology. 2nd ed. London, England: Informa Healthcare; 2004:11-25.
10. Lyman GH, Kuderer NM. The diagnosis and treatment of cancer in the elderly: cost effectiveness considerations. In: Balducci L, Lyman GH, Erschler W, Extermann M, eds. Comprehensive Geriatric Oncology. 2nd ed. London, England: Informa Healthcare; 2004:510-524.
11. Resnick B, McLeskey SW. Cancer screening across the aging continuum. Am J Manag Care. 2008;14(5):267-276.
12. Sarfaty M, Myers RE. The effect of HEDIS measurement of colorectal cancer screening on insurance plans in Pennsylvania. Am J Manag Care. 2008;14(5):277-282.
13. Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9(3):222-231.
14. Roetzheim RG, Chirikos TN, Wells KJ, et al. Managed care and cancer outcomes for Medicare beneficiaries with disabilities. Am J Manag Care. 2008;14(5):287-296.
15. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792.
16. Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care. 2008;14(5):297-306.
17. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524-4531.
18. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004;22(21):4302-4311.
19. Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007;110(7):1611-1620.
20. Lyman GH. Chemotherapy dose intensity and quality cancer care. Oncology. 2006;20(14)(suppl 9):16-25.
21. Aboumatar HJ, Winner LE, Davis RO, et al. No time to waste: decreasing patient wait times for chemotherapy administration using automated prioritization in an oncology pharmacy system. Am J Manag Care. 2008;14(5):309-316.
22. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258-2266.
23. Lyman GH, Bemdt ER, Kallich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health. 2005;8(2):149-156.
24. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care. 2008;14(5):317-322.
25. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25(28):4431-4437.
26. McKeage K, Plosker GL. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics. 2008;26(3):251-268.
27. Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Tech Assess. 2004;8(4):1-176.
28. Lyman GH. Time is money for both the healthy and the sick. Med Care. 2005;43(7):637-639.
29. Bardia A, Barton DL, Prokop LJ, Bauer BA, Moynihan TJ. Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. J Clin Oncol. 2006;24(34):5457-5464.
30. Longo CJ, Deber R, Fitch M, Williams AP, D'Souza D. An examination of cancer patients' monthly "out-of-pocket" costs in Ontario, Canada. Eur J Cancer Care. 2007;16(6):500-507.
31. Lafferty WE, Tyree PT, Devlin SM, Andersen MR, Diehr PK. Complementary and alternative medicine provider use and expenditures by cancer treatment phase. Am J Manag Care. 2008;14(5):326-334.
32. Ginsburg JA, Doherty RB, Ralston JF Jr, et al. Achieving a high-performance health care system with universal access: what the United States can learn from other countries. Ann Intern Med. 2008;148(1):55-75.